Bioenvision Receives Notification from Nasdaq Regarding Removal of ''E'' from Trading Symbol

Bioenvision, Inc. (Nasdaq: BIVN) today announced that
the Nasdaq Listings Qualifications Panel has approved its request for
continued listing on the Nasdaq National Market and advises that the
fifth character "E" will be removed from Bioenvision's trading symbol
effective on the opening of trading on Friday, July 1, 2005.
   As noted in prior press releases, the "E" had been added to the
Bioenvision trading symbol because the Company had not been in
compliance with Nasdaq's listing standards as a result of a delay in
filing its quarterly report on Form 10-QSB for the quarter ended March
31, 2005. The Form 10-QSB was subsequently filed on June 29, 2005. As
a result, the Nasdaq Listings Qualifications Panel has determined that
the Company now has satisfied its filing requirements and has
evidenced compliance with all other requirements necessary for
continued listing on the Nasdaq National Market.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development and
distribution of compounds and technologies for the treatment of
cancer. Bioenvision has a broad pipeline of products for the treatment
of cancer, including: Clofarabine (in co-development with Genzyme
Corporation), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies, including
the OLIGON technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices. For more
information on Bioenvision please visit our Web site at
www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.